Guggenheim Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $15.00

UroGen Pharma (NASDAQ:URGN - Get Free Report) had its target price reduced by Guggenheim from $40.00 to $15.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's target price suggests a potential upside of 281.19% from the company's previous close.

A number of other research firms have also recently commented on URGN. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a report on Thursday, May 8th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price for the company. Scotiabank began coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target on the stock. HC Wainwright downgraded shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a research report on Thursday. Finally, The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $27.43.

UroGen Pharma Trading Down 3.6%

NASDAQ URGN traded down $0.15 during trading on Friday, hitting $3.94. The company had a trading volume of 649,149 shares, compared to its average volume of 662,848. The company's fifty day moving average is $10.18 and its 200-day moving average is $10.73. UroGen Pharma has a one year low of $3.42 and a one year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market cap of $181.43 million, a price-to-earnings ratio of -1.25 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. On average, sell-side analysts predict that UroGen Pharma will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its holdings in shares of UroGen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after acquiring an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma in the 4th quarter worth approximately $59,000. Lazard Asset Management LLC bought a new position in shares of UroGen Pharma during the fourth quarter valued at approximately $67,000. GAMMA Investing LLC increased its holdings in UroGen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in UroGen Pharma in the fourth quarter worth approximately $101,000. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.